Personalized medicine IP in threat - consequences of Prometheus case June 28, 2012

Personalized medicine IP in threat - What are the possible consequences of the Prometheus case on your IP strategy?
Thursday, June 28, 2012

11:30 AM - 12:00 PM Registration, Networking & Lunch
12:00 PM - 01:00 PM Presentation & Q&A
01:00 PM - 02:00 PM Networking Dessert & Product Show

Gary Baker, Managing Director of the Quine IP Law Group, will discuss recent court cases, which effectively narrow the scope of acceptable subject matter for patent protection. In Mayo v. Prometheus (U.S. Supreme Court, No. 10-1150, argued December 7, 2011 - decided March 20, 2012), the relationship between serum thiopurine metabolite levels and the efficacy or toxicity of dosing was deemed an unpatentable law of nature. The Supreme Court held that simply appending conventional steps, specified at high level of generality, to laws of nature does not provide patentable subject matter.

Mr. Baker will discuss the history leading to Prometheus and possible practical effects with regard to analytical and treatment methods claims.

Immediately following the event, the BioCenter will host a Networking Dessert & Product Show, generously provided by Scientist Solutions Events. All attendees and BioCenter clients are invited to come out to enjoy food/refreshments/espresso bar/raffle and browse the vendor tables!

For more information & speaker's bio, please visit http://www.sjbiocenter.com/event/ev_2012Q2-PersonalizedMedicineIPinThreat.html

Registration:
Regular Price: $35**
Partners' Network: $25**
BioCenter Members: Free
On-site Registration, if space allows: same cost but bring your lunch...
**Register before Tuesday June 26th!

Official Website: http://www.sjbiocenter.com/event/ev_2012Q2-PersonalizedMedicineIPinThreat.html